Patent Issued for Engineered gyri-like mutein aptamers, and related methods (USPTO 12104201).

Crosslife Technologies Inc. has been issued a patent for engineered gyri-like mutein aptamers, which are non-native variant proteins designed from the Gyrl-like family of proteins. These aptamers, known as GYRAPTs or GYRYZYMEs, can bind to various target organic molecules and function as on/off bioswitches. The patent outlines methods for creating these aptamers through rational mutagenesis or mutant library screening, highlighting their potential applications in molecular imaging, diagnostics, and therapeutics. The Gyrl-like proteins used as scaffolds for these aptamers are small-molecule binding proteins found in prokaryotes and eukaryotes, offering a versatile platform for designing novel biotechnological tools. [Extracted from the article]